Ombitasvir/Paritaprevir/Ritonavir
- Generic Name
- Ombitasvir/Paritaprevir/Ritonavir
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于治疗成人基因1型慢性丙型肝炎，包括无肝硬化或伴代偿期肝硬化的患者。该治疗方案是全口服的、无干扰素、可联合或不联合利巴韦林。
- Associated Conditions
- -
- Associated Therapies
- -
eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 441
- Registration Number
- NCT04047680
- Locations
- 🇨🇳
National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 40
- Registration Number
- NCT03549832
- Locations
- 🇪🇬
Assiut University Hopsital, Assiut, Egypt
Effect Of DAAs For Treatment Of HCV On Normal Kidney
Phase 4
- Conditions
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 100
- Registration Number
- NCT03296930
Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02806362
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 256
- Registration Number
- NCT02803138
- Locations
- 🇮🇱
Ha'Emek Medical Center /ID# 153695, Afula, Israel
🇮🇱Assaf Harofeh Medical Center /ID# 153708, Be'er Ya'akov, Israel
🇮🇱The Edith Wolfson Medical Cent /ID# 153706, Holon, Israel
The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 101
- Registration Number
- NCT02582671
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 166
- Registration Number
- NCT02582632
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 565
- Registration Number
- NCT02581189
Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 314
- Registration Number
- NCT02581163
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3
- Registration Number
- NCT02504099
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath